Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 20, 2010

View Archived Issues

Bezafibrate-medroxyprogesterone combination active against AML

MAC-13243 represents a new antibacterial class with Gram-negative selectivity

Neural stem cells used to deliver HER2-targeting antibodies

Glucobay OD approved in Japan for diabetes

Date set for FDA Advisory Committee review of tesamorelin

Genzyme reports fourth quarter 2009 results

Boehringer and Priaxon sign collaboration for mdm2/p53 inhibitors in cancer

Founders of Proteon Therapeutics launch new company Novita Therapeutics

Viralytics reports results from phase I trial of Cavatak in late-stage melanoma

Lecithin-based nanoparticle adjuvant induces antibody immune responses

Polylactide-co-glycolide cancer vaccine regulates dendritic cell network for antitumor responses

Idera achieves clinical milestone under Merck collaboration for cancer treatment

Abbott claims nicotinic alpha4beta2 receptor modulators as analgesics

New compounds for the treatment of neurodegeneration claimed by sanofi-aventis

Novel oncolytic agents described by Bristol-Myers Squibb

Ranbaxy acquires vaccine products and manufacturing facility from Biovel

MorphoSys enrolls first patient in phase Ib/IIa clinical trial for MOR-103

AstraZeneca claims mGluR2 agonists for the treatment of schizophrenia

Depomed plans for one additional phase III trial for menopausal hot flashes

Biotie reports topline data from VAP-1 antibody trial in RA patients

RXi and UMMS sign research collaboration for sd-rxRNA in ocular diseases

Merz and BioForm Medical sign agreement and plan of merger

GenVec enters collaboration for hearing loss treatments

Avir Green Hills Biotechnology commences phase II deltaFLU study

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...